Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05514054
Title A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

Her2-receptor negative breast cancer

Therapies

Letrozole

Anastrozole

Exemestane

Tamoxifen

LY3484356

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT


No variant requirements are available.